Cardiovascular Burden of Narcolepsy Disease (CV-BOND): a real-world evidence study.

"Disclosure Statement Financial disclosure: RH Ben-Joseph and R Saad are former full-time employees of Jazz Pharmaceuticals who, in the course of this employment, received stock options exercisable for, and other stock awards of, ordinary shares of Jazz Pharmaceuticals plc. J Black is a part-time employee of Jazz Pharmaceuticals and shareholder of Jazz Pharmaceuticals. EC Dabrowski, B Taylor, and S Gallucci are full-time employees of Aetion, Inc. and hold stock options or equity in Aetion. VK Somers provides paid consulting services to Jazz Pharmaceuticals, and has also consulted for Respicardia, Bayer, and Sleep Number, and serves on the Sleep Number Scientific Advisory Board. Non-financial disclosure: none. Financial disclosure : RH Ben-Joseph and R Saad are former full-time employees of Jazz Pharmaceuticals who, in the course of this employment, received stock options exercisable for, and other stock awards of, ordinary shares of Jazz Pharmaceuticals plc. J Black is a part-time employee of Jazz Pharmaceuticals and shareholder of Jazz Pharmaceuticals. EC Dabrowski, B Taylor, and S Gallucci are full-time employees of Aetion, Inc. and hold stock options or equity in Aetion. VK Somers provides paid consulting services to Jazz Pharmaceuticals, and has also consulted for Respicardia, Bayer, and Sleep Number, and serves on the Sleep Number Scientific Advisory Board."

"This study was supported by Jazz Pharmaceuticals. At the direction of the authors, LeeAnn Braun, MPH, MEd and Karyn Liu, PhD of Peloton Advantage, LLC, an OPEN Health company, provided medical writing and editorial support, which was funded by Jazz Pharmaceuticals. All authors, including those from Jazz Pharmaceuticals, were involved in the design and/or conduct of the study; collection, management, analysis, and interpretation of the data; and preparation and review of the manuscript. All authors had full access to all data in the study and had final responsibility for the decision to submit for publication. Statistical review of the manuscript was performed by Elizabeth Poole, PhD of Jazz Pharmaceuticals. Some of the data in this publication were previously presented at the 35th Annual Meeting of the Associated Professional Sleep Societies, June 10–13, 2021 (virtual); at World Sleep, March 11–16, 2022 (Rome, Italy); and at the 74th American Academy of Neurology Annual Meeting, April 2–7, 2022 (Seattle, WA). Disclosure Statement: Financial disclosure: RH Ben-Joseph and R Saad are former full-time employees of Jazz Pharmaceuticals who, in the course of this employment, received stock options exercisable for, and other stock awards of, ordinary shares of Jazz Pharmaceuticals plc. J Black is a part-time employee of Jazz Pharmaceuticals and shareholder of Jazz Pharmaceuticals. EC Dabrowski, B Taylor, and S Gallucci are full-time employees of Aetion, Inc. and hold stock options or equity in Aetion. VK Somers provides paid consulting services to Jazz Pharmaceuticals, and has also consulted for Respicardia, Bayer, and Sleep Number, and serves on the Sleep Number Scientific Advisory Board.: Non-financial disclosure: none."